{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:20:40Z","timestamp":1792171240411,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270218, U22A20291"],"award-info":[{"award-number":["82270218, U22A20291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270218, U22A20291"],"award-info":[{"award-number":["82270218, U22A20291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-1-022, 2021-I2M-1-041, 2021-I2M-C&T-B-079"],"award-info":[{"award-number":["2022-I2M-1-022, 2021-I2M-1-041, 2021-I2M-C&T-B-079"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-1-022, 2021-I2M-1-041, 2021-I2M-C&T-B-079"],"award-info":[{"award-number":["2022-I2M-1-022, 2021-I2M-1-041, 2021-I2M-C&T-B-079"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06026-x","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T22:01:20Z","timestamp":1727906480000},"page":"5573-5581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["T(11;14) with multiple myeloma: Standard risk survival but slow and poor response"],"prefix":"10.1007","volume":"103","author":[{"given":"Yuntong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueshen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"issue":"24","key":"6026_CR1","first-page":"5640","volume":"58","author":"H Avet-Loiseau","year":"1998","unstructured":"Avet-Loiseau H, Li JY, Facon T et al (1998) High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Can Res 58(24):5640\u20135645","journal-title":"Can Res"},{"issue":"26","key":"6026_CR2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863\u20132869. https:\/\/doi.org\/10.1200\/jco.2015.61.2267","journal-title":"J Clin Oncol"},{"issue":"4","key":"6026_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V et al (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 88(4):360\u2013376. https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.019","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"6026_CR4","doi-asserted-by":"publisher","first-page":"8064","DOI":"10.1200\/JCO.2022.40.16_suppl.8064","volume":"40","author":"S Pirmohammed","year":"2022","unstructured":"Pirmohammed S, Joseph N, Hofmeister CC et al (2022) Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy. J Clin Oncol 40(1):8064\u20138064. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8064","journal-title":"J Clin Oncol"},{"issue":"1","key":"6026_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/leu.2017.204","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, AlhajMoustafa M, Rajkumar SV et al (2018) Natural history of t(11;14) multiple myeloma. Leukemia 32(1):131\u2013138. https:\/\/doi.org\/10.1038\/leu.2017.204","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"6026_CR6","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1182\/blood-2018-99-119051","volume":"132","author":"JL Kaufman","year":"2018","unstructured":"Kaufman JL, Joseph N, Gupta VA et al (2018) Outcomes of myeloma patients with t(11;14) Receiving lenalidomide, bortezomib, and dexamethasone (RVD) Induction Therapy. Blood 132(Supplement 1):3282\u20133282. https:\/\/doi.org\/10.1182\/blood-2018-99-119051","journal-title":"Blood"},{"issue":"6","key":"6026_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ejh.13325","volume":"103","author":"C Gran","year":"2019","unstructured":"Gran C, Uttervall K, Borg Bruchfeld J et al (2019) Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration? Eur J Haematol 103(6):588\u2013596. https:\/\/doi.org\/10.1111\/ejh.13325","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"6026_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-138888","volume":"136","author":"S Bal","year":"2020","unstructured":"Bal S, Giri S, Godby KN et al (2020) Redefining the Prognostic Significance of t(11;14) Multiple Myeloma. Blood 136(Supplement 1):43\u201343. https:\/\/doi.org\/10.1182\/blood-2020-138888","journal-title":"Blood"},{"key":"6026_CR9","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1182\/blood-2019-126867","volume":"134","author":"SK Kumar","year":"2019","unstructured":"Kumar SK, Lu J, Liu YT et al (2019) Outcomes of patients with t(11;14) Multiple myeloma: an international myeloma working group multicenter study. Blood 134:3066. https:\/\/doi.org\/10.1182\/blood-2019-126867","journal-title":"Blood"},{"issue":"1","key":"6026_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-023-00807-9","volume":"13","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E et al (2023) Multiple myeloma with t(11;14): impact of novel agents on outcome. Blood Cancer J 13(1):40. https:\/\/doi.org\/10.1038\/s41408-023-00807-9","journal-title":"Blood Cancer J"},{"issue":"22","key":"6026_CR11","doi-asserted-by":"publisher","first-page":"6781","DOI":"10.1158\/1078-0432.Ccr-19-0706","volume":"25","author":"N Saini","year":"2019","unstructured":"Saini N, Ma J, Milton DR et al (2019) Impact of autologous transplantation in patients with multiple myeloma with t(11;14): A propensity-score matched analysis. Clin Cancer Res 25(22):6781\u20136787. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0706","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6026_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/jha2.742","volume":"4","author":"KJ Lim","year":"2023","unstructured":"Lim KJ, Wellard C, Talaulikar D et al (2023) The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR). EJHaem 4(3):639\u2013646. https:\/\/doi.org\/10.1002\/jha2.742","journal-title":"EJHaem"},{"key":"6026_CR13","doi-asserted-by":"publisher","first-page":"538126","DOI":"10.3389\/fonc.2020.538126","volume":"10","author":"W Gao","year":"2020","unstructured":"Gao W, Du J, Liu J et al (2020) What multiple myeloma with t(11;14) should be classified into in novel agent era: Standard or intermediate risk? Front Oncol 10:538126. https:\/\/doi.org\/10.3389\/fonc.2020.538126","journal-title":"Front Oncol"},{"issue":"1","key":"6026_CR14","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/bjh.17627","volume":"195","author":"S Bal","year":"2021","unstructured":"Bal S, Giri S, Godby KN et al (2021) Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma. Br J Haematol 195(1):e113\u2013e116. https:\/\/doi.org\/10.1111\/bjh.17627","journal-title":"Br J Haematol"},{"issue":"3","key":"6026_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Ryan J, Guerriero J et al (2016) BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30(3):761\u2013764. https:\/\/doi.org\/10.1038\/leu.2015.184","journal-title":"Leukemia"},{"issue":"12","key":"6026_CR16","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"9","key":"6026_CR17","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.Ccr-14-2576","volume":"21","author":"G An","year":"2015","unstructured":"An G, Li Z, Tai YT et al (2015) The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res 21(9):2148\u20132156. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2576","journal-title":"Clin Cancer Res"},{"issue":"19","key":"6026_CR18","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","volume":"3","author":"Y Yan","year":"2019","unstructured":"Yan Y, Mao X, Liu J et al (2019) The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv 3(19):2895\u20132904. https:\/\/doi.org\/10.1182\/bloodadvances.2019000432","journal-title":"Blood Adv"},{"issue":"9","key":"6026_CR19","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00277-015-2426-8","volume":"94","author":"G Ihorst","year":"2015","unstructured":"Ihorst G, Waldschmidt J, Schumacher M et al (2015) Analysis of survival by tumor response: have we learnt any better? Ann Hematol 94(9):1615\u20131616. https:\/\/doi.org\/10.1007\/s00277-015-2426-8","journal-title":"Ann Hematol"},{"issue":"6","key":"6026_CR20","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/s2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM et al (2021) Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol 8(6):e422\u2013e432. https:\/\/doi.org\/10.1016\/s2352-3026(21)00130-7","journal-title":"Lancet Haematol"},{"issue":"21","key":"6026_CR21","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","volume":"115","author":"B Nair","year":"2010","unstructured":"Nair B, van Rhee F, Shaughnessy JD Jr et al (2010) Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance. Blood 115(21):4168\u20134173. https:\/\/doi.org\/10.1182\/blood-2009-11-255620","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06026-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06026-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06026-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:10:46Z","timestamp":1735866646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06026-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6026"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06026-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the Declaration of Helsinki and was approved by the local institutional ethics committees of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College (Certificate: IIT2020023-EC-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}